Association between obesity, molecular subtype, and immunotherapy outcomes in intrahepatic cholangiocarcinoma: The obesity paradox.

Journal of Clinical Oncology 2026

View at publisher
Authors: Fen Saj, Quentin Kimana, Elisabeth Kong, Lianchun Xiao, Nakul Manish Shah, Sunyoung S. Lee, Zishuo Ian Hu, Gabriel Dan Duda, Lawrence Ang Kian Kwong, Sangeeta Goswami, Anil Korkut, Milind M. Javle
DOI: 10.1200/jco.2026.44.2_suppl.587
Cited by: 1

Abstract

587 Background: Obesity and elevated body mass index (BMI) are associated with increased cancer risk yet paradoxically correlate with improved outcomes after immune checkpoint inhibition in lung cancer and melanoma. Their impact on treatment outcomes in intrahepatic cholangiocarcinoma (iCCA) remains unclear. We investigated the associations between BMI, genomic alterations, tumor immune microenvironment, and outcomes with chemoimmunotherapy (chemo-IO) in patients (pts) with iCCA. Methods: This retrospective study included pts with iCCA treated at a single center. Demographics, clinicopathologic characteristics, genomic profiles, and outcomes were extracted from electronic health records. Pts were stratified as obese (BMI ≥30) or non-obese (

Fields of Study & Subjects

Cholangiocarcinoma and Gallbladder Cancer Studies Multiple and Secondary Primary Cancers Gastric Cancer Management and Outcomes

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
2_suppl
Pages
587–587
Publication date
10 January 2026
Language
EN